State-private partnerships join hands to develop a nasal spray to stop covids, the latest through animal trials to prepare for clinical studies in volunteers. It is expected to be released in the third quarter of this year.
On February 28, 65, reporters reported 5 network partners from the public and private sectors, comprising Assoc. Prof. Dr. Chanchai Sitthiphan, Dean of the Faculty of Medicine. Chulalongkorn University, Asst. Prof. Chaichan Thawornwet, President of Silpakorn University, Dr. Nopporn Chuenklin, Director of the Institute for Health Systems Research (HSRI), Dr. Witoon Danwiboon, Director of the Government Pharmaceutical Organization and Commander-in-Chief Physician Prasit Damrong Director of Hibiosai Co., Ltd. was the representative to sign a memorandum of cooperation for innovation development. “A nasal spray antibody with anti-COVID-19 properties”
This important synergy To drive research and development of Thai innovations to the world level An innovative nasal spray antibody with anti-COVID-19 properties, which has been tested in preliminary animals with satisfactory results. And it is preparing to move on to clinical trials in volunteers within the first quarter of this year.
Then the results of the study will be submitted for registration with the Food and Drug Administration (FDA) around June 2022. It is expected to be released to the market in order to provide Thai people with access to alternative health innovations to prevent the spread of COVID-19. -19 Around the 3rd quarter of 2022
Assoc.Prof.Dr. Chanchai Sitthiphan, Dean of the Faculty of Medicine Chulalongkorn University said in the situation of COVID-19 Faculty of Medicine, Chulalongkorn University, together with various faculties To develop important national medical innovations such as the development of ChulaCov 19 vaccine, test kits, ventilators, etc. The organization is very pleased and proud to bring knowledge from research. by a team of medical researchers, Chulalongkorn University is the development of antibodies that have antibodies once morest COVID-19 specific and highly efficient
The research team has cultivated and developed since the beginning of the outbreak. It received support from both the public and government sectors, namely the Institute of Health Systems Research (HSRI), until it was able to develop a prototype antibody and filed a patent successfully. and is ready to transfer this knowledge to the private sector for further development in clinical research to create innovative products that should help prevent or treat COVID-19
also now There is cooperation of private sector agencies. together with the Pharmaceutical Organization who have recognized the importance and benefits of such innovations Continue to receive the knowledge gained from this research to continue clinical research. and developed to be a nasal spray antibody product that has anti-Covid-19 properties. The agencies that cooperate in this time will conduct clinical research. And produce according to the standards to request for product registration with the Food and Drug Administration (FDA) so that people can use this product with confidence. And it’s another way to help cope with the Covid-19 epidemic situation.
“The knowledge from this research and collaboration will result in another successful key innovation. and help Thailand get out of the Covid-19 epidemic situation this time safely.”Prof. Dr. Chanchai said.
Asst. Prof. Chaichan Thawornwet, President of Silpakorn University said that Silpakorn University by Prof. Dr. Praneet Opanasopit, together with Assoc. Prof. Dr. Por. Prasopchai Patrojanasopon and the working group of the Faculty of Pharmacy has participated in a research study with a research team from the Faculty of Medicine Chulalongkorn University To develop a prototype antibody spray for nasal spray to prevent COVID-19 From the results of preliminary experiments at the laboratory level and animal research studies Developed Nasal Spray Antibody Effectively Suppresses COVID-19
Silpakorn University sincerely hopes that research and development and the cooperation that occurred in this This will result in health innovations for Thai people. It is a part that will help Thailand get through the epidemic situation of Covid-19.
Dr. Nopporn Chuenklin, director of the Institute of Public Health Research (HSRI), said that the innovation of “antibody spray nasal spray with anti-COVID-19 properties” is being developed and has been studied for its efficacy. in that human It is a continuation of the research that HISTORY has supported in the project “Development of Monoclonal antibody cocktail once morest SAR-CoV-2 from COVID-19 patients. who have recovered from the disease”. for the goal of fulfilling health security including equal access to health services for Thai people And health innovations will help Thai people to become more self-reliant on health.
“This sponsorship for research grants in health innovations of HISTORY is another important step in promoting commercial health innovations. and also to support the potential of researchers To lead the development of innovation through cooperation with all sectors. both public and private Ready to raise confidence in research / innovation to have a standard and covers clinical research as well as in human trials.” Dr. Nopporn said.
Dr. Witoon Danwiboon, Director of the Government Pharmaceutical Organization, said that the GPO is the main organization in the production and supply of medicines and medical supplies in the situation of COVID-19. come continuously and aiming to promote innovative health products that can be produced and used in the country with expertise in the manufacture of medicines and medical supplies with internationally accepted standards
The Pharmaceutical Organization has played a role in the production. Innovative product “Antibody Nasal Spray with Anti-COVID-19 Properties” for use in clinical studies in volunteers. to study the effectiveness and safety It is the information for applying for registration with the Food and Drug Administration (FDA).
The cooperation of the network partners of all 5 agencies this time. This is a new platform for collaboration that creates health innovations to drive health care for Thai people. Ready to deal with the epidemic situation of COVID-19 that occur in the present and the future with strength and sustainability
Lieutenant Colonel Prasit Damrong, Director of Hibiosi Co., Ltd., said that over the past two years, the COVID-19 virus has emerged and spread until it has a widespread impact. both for the economy and the lives of people around the world public health measures and encouraging people to get vaccinated It is an important strategy to reduce infection rates. Including the mortality rate of people in each country, but there are still many people who are not immune from vaccines. or the landscape that does not exist for a long time Cannot prevent infection with COVID-19
“Hi Biosci Co., Ltd. intends to drive innovation. A nasal spray product containing human antibodies specific to COVID-19. invented by Thai doctors which answers the question of enhancing immunity in the nasal cavity, which is the front line that will trap the virus from entering the lower respiratory tract It aims to develop this innovation as an alternative product to prevent the spread of COVID-19. another way which is considered an innovation for Thai people for Thai people
It will prepare for product registration within the first quarter and expand the distribution to reach Thai people within the third quarter of this year to promote stability in the country’s health system. In addition, the company There is also a plan to expand the results to the international market. to promote and drive Thai innovation to the world stage as well,” said Dr. Paporn.
In this regard, the cooperation of all 5 network partners with specific expertise Jointly develop innovations throughout the supply chain, starting from the development of innovative antibodies with specific properties to protect once morest COVID-19. Supporting funds for further research development into products in spray form that are effective and convenient to use.
as well as standardized production processes Produced as a prototype finished product and released to the market for practical use This is a new platform for cooperation that creates a model of health innovation to drive health care for Thai people to be ready to cope with the epidemic situation of COVID-19. that occur in the present and the future with strength and sustainability
Read related news.